Cross-validation of brain segmentation by SPM5 and SIENAX.

Psychiatry Res

Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA.

Published: November 2008

Volumes of cerebral grey (GM) or white matter (WM) are often used as clinical observations or statistical covariates. Several automated segmentation tools can be used for this purpose, but they have not been validated against each other. We used the most common ones, SPM5 and SIENAX 2.4, to derive volumes of grey and white matter in 56 healthy subjects (mean age 49+/-13, range 22-80) and compared the two methods. Both methods yielded significant correlations with age in the expected directions, and estimates of parenchymal volumes were highly correlated. However, without use of prior probability maps, or priors, in SIENAX, GM was significantly underestimated in comparison to SPM (0.52+/-.06 vs 0.66+/-.07 L) and WM was significantly overestimated (0.48+/-.07 vs 0.46+/-.07 L). This error was associated with misclassification of GM as cerebrospinal fluid, especially in deep grey matter. Invoking prior probabilities in SIENAX resulted in excellent agreement with SPM: GM and WM volumes were found to be 0.64+/-0.07 L and 0.47+/-0.07 L, respectively. We conclude that SIENAX requires priors for accurate volumetric estimates, and then provides close agreement with SPM5.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778005PMC
http://dx.doi.org/10.1016/j.pscychresns.2007.12.008DOI Listing

Publication Analysis

Top Keywords

spm5 sienax
8
grey white
8
white matter
8
sienax
5
cross-validation brain
4
brain segmentation
4
segmentation spm5
4
volumes
4
sienax volumes
4
volumes cerebral
4

Similar Publications

Cross-validation of brain segmentation by SPM5 and SIENAX.

Psychiatry Res

November 2008

Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA.

Volumes of cerebral grey (GM) or white matter (WM) are often used as clinical observations or statistical covariates. Several automated segmentation tools can be used for this purpose, but they have not been validated against each other. We used the most common ones, SPM5 and SIENAX 2.

View Article and Find Full Text PDF

Measurement of brain atrophy has been proposed as a surrogate marker in MS and degenerative dementias. Although cerebral small vessel disease predominantly affects white and subcortical grey matter, recent data suggest that whole brain atrophy is also a good indicator of clinical and cognitive status in this disease. Automated methods to measure atrophy are available that are accurate and reproducible in disease-free brains.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!